Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Jump-Start Your Search For Promising Trade Ideas With Barchart Premier’s "Top Stock Pick". FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Gilead Sciences Inc (GILD)

Gilead Sciences Inc (GILD)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Gilead Sciences Inc 333 LAKESIDE DRIVE FOSTER CITY CA 94404 USA

www.gilead.com Employees: 18,000 P: 650-574-3000 F: 650-522-5853

Description:

Gilead Sciences is a pioneer in developing drugs for the treatment of human immunodeficiency virus, liver diseases, hematology/oncology diseases and inflammation/respiratory diseases. The company has a strong HIV franchise with key HIV/AIDS therapies like tenofovir alafenamide based products - Genvoya, Odefsey, Descovy, Biktarvy and Truvada. The portfolio also includes hepatitis C virus drugs like Harvoni and Epclusa and HBV drug. The first cell therapy approved for the treatment of adult patients with relapsed or refractory large B-cell lymphoma, has diversified Gilead's portfolio. Tecartus, another CAR T-cell therapy, was granted an accelerated approval in the United States for the treatment of relapsed or refractory mantle cell lymphoma. The company is also working on diversifying and growing its business beyond antivirals into other therapeutic areas. Gilead is also making inroads in the oncology space with strategic collaborations and acquisitions.

Key Statistics

Overview:

Market Capitalization, $K 105,386,704
Enterprise Value, $K 125,568,704
Shares Outstanding, K 1,245,853
Annual Sales, $ 27,116 M
Annual Net Income, $ 5,665 M
Last Quarter Sales, $ 6,954 M
Last Quarter Net Income, $ 1,614 M
EBIT, $ 2,558 M
EBITDA, $ 5,251 M
60-Month Beta 0.18
% of Insider Shareholders 0.16%
% of Institutional Shareholders 83.67%
Float, K 1,243,860
% Float 99.84%
Short Volume Ratio 0.48

Growth:

1-Year Return 13.18%
3-Year Return 24.31%
5-Year Return 32.19%
5-Year Revenue Growth 22.55%
5-Year Earnings Growth 9.27%
5-Year Dividend Growth 31.58%

Per-Share Information:

Most Recent Earnings 2.01 on 08/08/24
Next Earnings Date 11/07/24
Earnings Per Share ttm 4.70
EPS Growth vs. Prev Qtr 252.27%
EPS Growth vs. Prev Year 50.00%
Annual Dividend Rate, $ 3.06
Annual Dividend Yield 3.62%
Most Recent Dividend 0.770 on 09/13/24
Next Ex-Dividends Date 09/13/24
Dividend Payable Date 09/27/24
Dividend Payout Ratio 64.02%
Most Recent Split 2-1 on 01/28/13

GILD Ratios

Ratio
Price/Earnings ttm 17.91
Price/Earnings forward 22.41
Price/Earnings to Growth 2.93
Return-on-Equity % 29.34%
Return-on-Assets % 10.10%
Profit Margin % 20.89%
Debt/Equity 1.28
Price/Sales 3.86
Price/Cash Flow 9.47
Price/Book 5.80
Book Value/Share 14.61
Interest Coverage 8.27

GILD Dividends

Date Value
09/13/24 $0.7700
06/14/24 $0.7700
03/14/24 $0.7700
12/14/23 $0.7500
09/14/23 $0.7500
06/14/23 $0.7500
03/14/23 $0.7500
12/14/22 $0.7300
09/14/22 $0.7300
06/14/22 $0.7300
03/14/22 $0.7300
12/14/21 $0.7100
09/14/21 $0.7100
06/14/21 $0.7100
03/12/21 $0.7100
12/14/20 $0.6800
09/14/20 $0.6800
06/11/20 $0.6800
03/12/20 $0.6800
12/12/19 $0.6300
09/12/19 $0.6300
06/13/19 $0.6300
03/14/19 $0.6300
12/13/18 $0.5700
09/13/18 $0.5700
06/14/18 $0.5700
03/15/18 $0.5700
12/14/17 $0.5200
09/14/17 $0.5200
06/14/17 $0.5200
03/14/17 $0.5200
12/13/16 $0.4700
09/14/16 $0.4700
06/14/16 $0.4700
03/14/16 $0.4300
12/14/15 $0.4300
09/14/15 $0.4300
06/12/15 $0.4300
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar